Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Biotechnology
  4. Volume 26, Issue 2
  5. Article
Volume 26, Issue 2
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Background

Breast Cancer (BRCA) is one of the most common cancers worldwide. Abnormal Alternative Splicing (AS) is frequently observed in cancers. Understanding the intricate relationship between gene mutations and abnormal AS is vital for developing novel diagnostic and therapeutic strategies to effectively target cancer.

Objective

This study aimed to focus on the analysis of transcriptomic splicing events in patients with Breast Cancer (BRCA), particularly those with mutations in the TP53 gene. Understanding the role of AS may be helpful in revealing potential predictive indicators for survival and treatment strategies.

Methods

The splicing data were downloaded from the Cancer Genome Atlas (TCGA) breast cancer project, incorporating 972 patients in the study, classified according to TP53 mutation status. A comprehensive splicing profile of these breast tumors was outlined, and an interaction network of Alternative Splicing (AS) events and splicing factors was constructed. This allowed for the identification of specific AS events associated with TP53-mutant breast cancer. A prognostic risk model based on AS events was established, using univariate and multivariate Cox regression analyses. To understand the molecular heterogeneity, consensus clustering analyses of prognostic AS events were performed. We also investigated the association of AS patterns with the immune microenvironment and drug sensitivity.

Results

A total of 4519 significant Alternative Splicing (AS) events were distributed among 2729 genes that were altered in TP53 mutant tumors. Based on the analysis of these events, a prognostic risk model was created involving ten AS events from ten genes (such as NKTR, CD46, VCAN, .). The survival analysis showed that patients with high-risk scores had significantly poorer overall survival (<0.001, HR=2.46, 95% CI 1.90-3.18) than those with low-risk scores. Furthermore, the study identified four molecular subtypes related to AS events (C1, C2, C3, and C4), which showed significant differences in immune cell infiltration, with C1 and C4 clusters having a higher degree of immune cell infiltration than C2 and C3. The chemosensitivity analysis revealed that these different AS clusters have different sensitivities to several anticancer drugs, such as docetaxel, paclitaxel, and doxorubicin, with C1 and C4 clusters being more sensitive than the other clusters.

Conclusion

We have demonstrated differential transcriptomic splicing events between TP53 mutant and wild-type cases of breast cancer, establishing an effective prognostic risk model based on AS events. These findings provide new insights that may aid in understanding the biological behavior of breast cancer and potentially in optimizing treatment strategies for breast cancer.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010283176240212073417
2024-02-23
2025-01-13

  • From This Site

    /content/journals/cpb/10.2174/0113892010283176240212073417
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FranciesF.Z. BassaS. ChatziioannouA. KaufmannA.M. DlaminiZ. Splicing genomics events in cervical cancer: Insights for phenotypic stratification and biomarker potency.Genes202112213010.3390/genes1202013033498485
     [Google Scholar]
  2. AlfarsiL.H. El-AnsariR. CrazeM.L. MasisiB.K. MohammedO.J. EllisI.O. RakhaE.A. GreenA.R. Co-expression effect of SLC7A5/SLC3A2 to predict response to endocrine therapy in oestrogen-receptor-positive breast cancer.Int. J. Mol. Sci.2020214140710.3390/ijms2104140732093034
     [Google Scholar]
  3. ZhaoH. MartinE. MatalkahF. ShahN. IvanovA. RuppertJ.M. LockmanP.R. AgazieY.M. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.Oncogene201938132275229010.1038/s41388‑018‑0574‑830467378
     [Google Scholar]
  4. AdamsC.M. MitraR. XiaoY. MichenerP. PalazzoJ. ChaoA. GourJ. CasselJ. SalvinoJ.M. EischenC.M. Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative Breast cancer.Cancer Discov.20231351210122910.1158/2159‑8290.CD‑22‑113136734633
     [Google Scholar]
  5. MilicevicZ. KasapovicJ. GavrilovicL. MilovanovicZ. BajicV. Spremo-PotparevicB. Mutant p53 protein expression and antioxidant status deficiency in breast cancer.EXCLI J.20141369170826417293
     [Google Scholar]
  6. WangC. ZhouZ. SubhramanyamC.S. CaoQ. HengZ.S.L. LiuW. FuX. HuQ. SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells.Commun. Biol.20203126810.1038/s42003‑020‑0983‑432461560
     [Google Scholar]
  7. QianW. LiangH. ShiJ. JinN. Grundke-IqbalI. IqbalK. GongC.X. LiuF. Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A.Nucleic Acids Res.201139146161617110.1093/nar/gkr19521470964
     [Google Scholar]
  8. PucciS. BonannoE. PichiorriF. AngeloniC. SpagnoliL.G. Modulation of different clusterin isoforms in human colon tumorigenesis.Oncogene200423132298230410.1038/sj.onc.120740414755245
     [Google Scholar]
  9. KhouryM.P. BourdonJ.C. The isoforms of the p53 protein.Cold Spring Harb. Perspect. Biol.201023a00092710.1101/cshperspect.a00092720300206
     [Google Scholar]
  10. Bieging-RolettK.T. KaiserA.M. MorgensD.W. BoutelleA.M. SeoaneJ.A. Van NostrandE.L. ZhuC. HoulihanS.L. MelloS.S. YeeB.A. McClendonJ. PierceS.E. WintersI.P. WangM. ConnollyA.J. LoweS.W. CurtisC. YeoG.W. WinslowM.M. BassikM.C. AttardiL.D. Zmat3 is a key splicing regulator in the p53 tumor suppression program.Mol. Cell2020803452469.e910.1016/j.molcel.2020.10.02233157015
     [Google Scholar]
  11. RyanM. WongW.C. BrownR. AkbaniR. SuX. BroomB. MelottJ. WeinsteinJ. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer.Nucleic Acids Res.201644D1D1018D102210.1093/nar/gkv128826602693
     [Google Scholar]
  12. ChenB. KhodadoustM.S. LiuC.L. NewmanA.M. AlizadehA.A. Profiling tumor infiltrating immune cells with CIBERSORT.Methods Mol. Biol.2018171124325910.1007/978‑1‑4939‑7493‑1_1229344893
     [Google Scholar]
  13. LiT. FuJ. ZengZ. CohenD. LiJ. ChenQ. LiB. LiuX.S. TIMER2.0 for analysis of tumor-infiltrating immune cells.Nucleic Acids Res.202048W1W509W51410.1093/nar/gkaa40732442275
     [Google Scholar]
  14. YuG. WangL.G. HeQ.Y. ChIPseeker: An R/Bioconductor package for ChIP peak annotation, comparison and visualization.Bioinformatics201531142382238310.1093/bioinformatics/btv14525765347
     [Google Scholar]
  15. ZhongW. WuY. ZhuM. ZhongH. HuangC. LinY. HuangJ. Alternative splicing and alternative polyadenylation define tumor immune microenvironment and pharmacogenomic landscape in clear cell renal carcinoma.Mol. Ther. Nucleic Acids20222792794610.1016/j.omtn.2022.01.01435211354
     [Google Scholar]
  16. ChenX. XuR. HeD. ZhangY. ChenH. ZhuY. ChengY. LiuR. ZhuR. GongL. XiaoM. WangZ. DengL. CaoK. CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer.Oncogene202140436223623410.1038/s41388‑021‑02019‑634552192
     [Google Scholar]
  17. YangW. SoaresJ. GreningerP. EdelmanE.J. LightfootH. ForbesS. BindalN. BeareD. SmithJ.A. ThompsonI.R. RamaswamyS. FutrealP.A. HaberD.A. StrattonM.R. BenesC. McDermottU. GarnettM.J. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells.Nucleic Acids Res.201341Database issueD955D96123180760
     [Google Scholar]
  18. WuQ. QianW. SunX. JiangS. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.J. Hematol. Oncol.202215114310.1186/s13045‑022‑01362‑936209184
     [Google Scholar]
  19. WangQ. ShaoX. ZhangY. ZhuM. WangF.X.C. MuJ. LiJ. YaoH. ChenK. Role of tumor microenvironment in cancer progression and therapeutic strategy.Cancer Med.20231210111491116510.1002/cam4.569836807772
     [Google Scholar]
  20. SinghR.K. KumarS. PrasadD.N. BhardwajT.R. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.Eur. J. Med. Chem.201815140143310.1016/j.ejmech.2018.04.00129649739
     [Google Scholar]
  21. DhimanA. SharmaR. SinghR.K. Target-based anticancer indole derivatives and insight into structure-activity relationship: A mechanistic review update (2018-2021).Acta Pharm. Sin. B20221273006302710.1016/j.apsb.2022.03.02135865090
     [Google Scholar]
  22. HainautP. PfeiferG.P. Somatic TP53 mutations in the era of genome sequencing.Cold Spring Harb. Perspect. Med.2016611a02617910.1101/cshperspect.a02617927503997
     [Google Scholar]
  23. ChenJ. WeissW.A. Alternative splicing in cancer: Implications for biology and therapy.Oncogene201534111410.1038/onc.2013.57024441040
     [Google Scholar]
  24. SinghR.K. Key heterocyclic cores for smart anticancer drug-design Part II.Bentham Science Publishers202210.2174/97898150400741220101
     [Google Scholar]
  25. XuL.D. ÖhmanM. ADAR1 editing and its role in cancer.Genes20181011210.3390/genes1001001230585209
     [Google Scholar]
  26. DueñasM. Pérez-FigueroaA. OliveiraC. Suárez-CabreraC. SousaA. OliveiraP. VillacampaF. ParamioJ.M. Martínez-FernándezM. Gene expression analyses in non muscle invasive bladder cancer reveals a role for alternative splicing and Tp53 status.Sci. Rep.2019911036210.1038/s41598‑019‑46652‑431316092
     [Google Scholar]
  27. LópezM.J. CarbajalJ. AlfaroA.L. SaraviaL.G. ZanabriaD. AraujoJ.M. QuispeL. ZevallosA. BulejeJ.L. ChoC.E. SarmientoM. PintoJ.A. FajardoW. Characteristics of gastric cancer around the world.Crit. Rev. Oncol. Hematol.202318110384110.1016/j.critrevonc.2022.10384136240980
     [Google Scholar]
  28. DankóB. SzikoraP. PórT. SzeifertA. SebestyénE. Splicing Factory-splicing diversity analysis for transcriptome data.Bioinformatics202238238439010.1093/bioinformatics/btab64834499147
     [Google Scholar]
  29. LiH. YangJ. YangG. RenJ. MengY. QiP. WangN. Identification of prognostic alternative splicing events in sarcoma.Sci. Rep.20211111494910.1038/s41598‑021‑94485‑x34294833
     [Google Scholar]
  30. HanY. LiuS.Y.M. JinR. MengW. WuY.L. LiH. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.Front. Immunol.202314117819310.3389/fimmu.2023.117819337492578
     [Google Scholar]
  31. RapoportB.L. SteelH.C. BennC.A. NaylerS. SmitT. HeymanL. TheronA.J. HlatshwayoN. KwofieL.L.I. MeyerP.W.A. AndersonR. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.Front. Oncol.202313109730910.3389/fonc.2023.109730937064132
     [Google Scholar]
  32. ChengY. WangC. WangH. ZhangZ. YangX. DongY. MaL. LuoJ. Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy.BMC Med.202220141110.1186/s12916‑022‑02614‑836303207
     [Google Scholar]
  33. QuanZ. YangY. ZhengH. ZhanY. LuoJ. NingY. FanS. Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer.J. Cancer202213133434344310.7150/jca.7761936313041
     [Google Scholar]
/content/journals/cpb/10.2174/0113892010283176240212073417
Loading
Clinical and Prognostic Implications of an Alternative Splicing-related Risk Model Based on TP53 Status in Breast Cancer
Current Pharmaceutical Biotechnology 26, 246 (2025); https://doi.org/10.2174/0113892010283176240212073417
/content/journals/cpb/10.2174/0113892010283176240212073417
/content/journals/cpb/10.2174/0113892010283176240212073417
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): alternative splicing; Breast cancer; gene mutation; immunotherapy; prognosis; TP53

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test